Inhalable drug given green light

News

Author: Simge Eva DoganPublished: 9 January 2019

Prep: Cook: Serves:

The US Food and Drug Administration (FDA) has approved INBRIJA – an inhalable drug created by US biotech company Acorda Therapeutics – for intermittent treatment.

INBRIJA is designed to treat Parkinson’s symptoms that occur between oral doses of medication, which are known as ‘off’ episodes. The drug has been approved by the FDA and – after a clinical study involving 900 people with Parkinson’s – is expected to be available in 2019.

Todd Sherer, CEO of The Michael J Fox Foundation, who funded early trials of the powder, said: “Despite being on treatment, patients may experience OFF periods as Parkinson’s progresses, which can be disruptive.

“We knew we had to help address this unmet need, and this approval is a significant step forward for the community as it provides a new option to manage these gaps in symptom control.”

To read more on this topic click here.

For more information on Parkinson’s medication please visit the EPDA website.

Memory loss could be an indication of Parkinson’s

Last Month

Next Month

Go Back

Share this story

Comments

Special reports

Muhammad Ali’s death “has raised Parkinson’s awareness”

Muhammad Ali’s legacy lives on

Journalist Liz Jackson’s emotional film about her Parkinson’s is “TV at its finest”

An outpouring of sympathy for award-winning journalist

83-year-old invents Parkinson’s ‘retainer’ to deliver oral levodopa via the mouth

New device delivers oral levodopa at continuous, controlled rate

Could treadmill training improve Parkinson’s symptoms?

Researchers at a German university have found that using a treadmill may improve gait in people with Parkinson’s. As part of the study – published in medical journal ‘Human Movement Science’ – 38 participants living with the condition completed 40 minutes of treadmill training twice a week for a period of eight weeks. Of that group, 18 varied the surface incline on the treadmill while the other 20 did not. While the results showed improved gait in both training groups, those that varied the incline saw significant improvement in stride length, stance and walking speed. The researchers, based at Friedrich-Alexander University Erlangen-Nürnberg, Germany said: “[Parkinson’s disease] patients demonstrated marked gait adaptations to the eight-week treadmill intervention, which were partially retained after three months follow-up”.

EPDA signs new charter on workplace rights

The European Parkinson’s Disease Association (EPDA) has signed the Dying to Work Charter – a pledge protecting the workplace rights of people with serious conditions. The charter – part of the Trade Union Congress’ wider Dying to Work campaign – has so far protected over half a million workers in the UK. The Dying to Work campaign group, chaired by MEP Rory Palmer, is calling on the European Union to amend its current legislation. The campaign is asking for serious conditions to be identified as a ‘protected characteristic’ – meaning employees would enjoy a protected period after diagnosis which would ensure the couldn’t be unfairly dismissed. Russell Patten, secretary general at the EPDA, said: “At the EPDA, we are committed to improving employment conditions, reducing stigma and ensuring accessibility to essential services for all people with Parkinson’s disease.” Image: Rory Palmer MEP (left) and Russell Patten, secretary general at the EPDA…

New wearable device could counteract gait

Scientists at the National University of Ireland Galway have created a wearable device that they believe will help people with Parkinson’s to walk more easily. The device, named cueStim, is worn around the waist and delivers fixed rhythmic sensory stimulation to the wearer. This will counteract ‘freezing of gait’ symptoms that are often experienced by people living with the condition. The scientists collaborated with professionals from UK medical board NHS Greater Glasgow and Clyde to test the device, and found that it significantly reduced the time taken for a person with Parkinson’s to complete walking tasks. Gearóid Ó Laighin, professor of electrical engineering at NUI Galway, said: “We are now seeking additional clinical partners to work with NUI Galway in carrying out a comprehensive long-term clinical evaluation of cueStim in enhancing the quality of life of people with Parkinson’s disease through a funded programme of research.”

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Comments
This field is for validation purposes and should be left unchanged.

Inhalable drug given green light

News

Author: Simge Eva DoganPublished: 9 January 2019

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Special reports

Muhammad Ali’s death “has raised Parkinson’s awareness”

Perspectives

Journalist Liz Jackson’s emotional film about her Parkinson’s is “TV at its finest”

Advances

83-year-old invents Parkinson’s ‘retainer’ to deliver oral levodopa via the mouth

Could treadmill training improve Parkinson’s symptoms?

EPDA signs new charter on workplace rights

New wearable device could counteract gait

{title}

Subscribe

Inhalable drug given green light

News

Author: Simge Eva DoganPublished: 9 January 2019

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Related articles

Special reports

Muhammad Ali’s death “has raised Parkinson’s awareness”

Perspectives

Journalist Liz Jackson’s emotional film about her Parkinson’s is “TV at its finest”

Advances

83-year-old invents Parkinson’s ‘retainer’ to deliver oral levodopa via the mouth

Could treadmill training improve Parkinson’s symptoms?

EPDA signs new charter on workplace rights

New wearable device could counteract gait

{title}

Subscribe

Sign in